| Name | Title | Contact Details |
|---|
MVNA serves individuals and families that are economically disadvantaged and at high risk for critical social and health issues. More than 90% of MVNA clients residing in Minneapolis are living at or below 200% of Federal Poverty Guidelines. Many of
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
Decade of Discovery is a major research initiative led by the Minnesota Partnership for Biotechnology and Medical Genomics focused on preventing, optimally treating and ultimately curing diabetes.
Arizona Hospital And Health Care Association is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Highmark Blue Cross Blue Shield West Virginia is a Parkersburg, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.